Chronic dietary supplementation with L-arginine inhibits platelet aggregation and thromboxane A2 synthesis in hypercholesterolaemic rabbits in vivo

Cardiovascular Research

Volumn 37, Issue 3, 1998, Pages 756-764

  Bode Böger, Stefanie M ^a   Böger, Rainer H ^a   Kienke, Sven ^a   Böhme, Michael ^a   Phivthong Ngam, Laddaval ^a   Tsikas, Dimitrios ^a   Frölich C, Jürgen ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Endothelium; Gas chromatography mass spectrometry; Nitric oxide; Platelet aggregation; Prostacyclin

Indexed keywords

ARGININE; CHOLESTEROL; PROSTACYCLIN; PROSTAGLANDIN F1 ALPHA; PROSTANOID; THROMBOXANE A2; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

AMINO ACID TRANSPORT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; CELL INTERACTION; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENDOTHELIUM CELL; HYPERCHOLESTEROLEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOCYTE AGGREGATION INHIBITION; URINARY EXCRETION;

ADENOSINE DIPHOSPHATE; ANIMALS; AORTA; ARGININE; BIOLOGICAL MARKERS; CREATININE; DIET; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HYPERCHOLESTEROLEMIA; MALE; NITRATES; NITROPRUSSIDE; PLATELET AGGREGATION; RABBITS; THROMBOXANE A2; THROMBOXANE B2; VASODILATOR AGENTS;

EID: 0032029268     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00295-2     Document Type: Article

References (46)

1. [1] Förstermann U, Mügge A, Alheid U, Haverich A, Frölich JC. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ Res 1988;62:185-190.
2. [2] Guerra R Jr, Brotherton AFA, Goodwin PJ, Clark CR, Armstrong ML, Harrison DG. Mechanisms of abnormal endothelium-dependent vascular relaxation in atherosclerosis: Implications for altered autocrine and paracrine functions of EDRF. Blood Vessels 1989;26:300-314.
3. 2 biosynthesis capacities of heart, arteries and platelets at various stages of experimental atherosclerosis in rabbits. Atherosclerosis 1978;31:385-394.
4. [4] Radomski MW, Palmer RMJ, Moncada S. Characterization of the L-arginine: nitric oxide pathway in human platelets. Br J Pharmacol 1987;101:325-328.
5. [5] Bunting S, Gryglewski R, Moncada S, Vane JR. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 1976;12:897-913.
6. [6] Armstrong ML, Peterson RE, Hoak JC, Megan MB, Cheng FH, Clarke WR. Arterial platelet accumulation in experimental hypercholesterolemia. Atherosclerosis 1980;36:89-100.
7. [7] Carvalho ACA, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974;290:434-438.
8. 2 formation in type-II hyperlipoproteinaemic patients. Eur J Clin Invest 1984;14:329-333.
9. [9] Vanhoutte PM. Platelet-derived serotonin, the endothelium, and cardiovascular disease. J Cardiovasc Pharmacol 1991;17:S6-S12. Suppl. 5.
10. [10] Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809.
11. [11] Kaul S, Padgett RC, Waack BJ, Brooks RM, Heistad DD. Effect of atherosclerosis on responses of the perfused rabbit carotid artery to human platelets. Arterioscler Thromb 1992;12:1206-1213.
12. 2, and atherosclerosis in young hypercholesterolemic swine. Prostag Leukot Essent Fatty Acids 1994;51:293-298.
13. [13] Marcus AJ, Weksler BB, Jaffe EA, Broekman MJ. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest 1980;66:979-986.
14. [14] Schafer AI, Crawford DD, Gimbrone MA Jr.. Unidirectional transfer of prostaglandin endoperoxides between platelets and endothelial cells. J Clin Invest 1984;73:1105-1112.
15. [15] Chesterman CN, Owe-Young R, MacPherson J, Krilis SA. Substrate for endothelial prostacyclin production in the presence of platelets exposed to collagen is derived from the platelets rather than the endothelium. Blood 1986;67:1744-1750.
16. [16] Bunting S, Moncada S, Vane JR. The prostacyclin-thromboxane balance: pathophysiological and therapeutic implications. Br Med Bull 1983;39:271-276.
17. [17] FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983;67:1174-1177.
18. [18] Böger RH, Bode-Böger SM, Schröder EP, Tsikas D, Frölich JC. Increased prostacyclin production during exercise in untrained and trained men: effect of low-dose aspirin. J Appl Physiol 1995;78:1832-1838.
19. [19] Böger RH, Bode-Böger SM, Gutzki Fm, Tsikas D, Weskott HP, Frölich JC. Rapid and selective inhibition of platelet aggregation and thromboxane formation by intravenous low dose aspirin in man. Clin Sci 1993;84:517-524.
20. [20] Böger RH, Bode-Böger SM, Mügge A, Kienke S, Brandes R, Dwenger A, Frölich JC. Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis 1995;117:273-284.
21. 3 - excretion a an indicator of nitric oxide formation in vivo during oral administration of L-arginine or L-NAME in rats. Clin Exp Pharmacol Physiol 1996;23:11-15.
22. [22] Bode-Böger SM, Böger RH, Alfke H, Heinzel D, Tsikas D, Creutzig A, Alexander K, Frölich JC. L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. Circulation 1996;93:85-90.
23. [23] Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992;90:1168-1172.
24. [24] Mügge A, Brandes R, Böger RH, Dwenger A, Bode-Böger S, Kienke S, Frölich JC, Lichtlen PR. Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 1994;24:994-998.
25. [25] Bode-Böger SM, Böger RH, Creutzig A, Tsikas D, Gutzki FM, Alexander K, Frölich JC. L-arginine infusion decreases peripheral resistance and inhibits platelet aggregation in healthy subjects. Clin Sci 1994;87:303-310.
26. [26] Tsikas D, Gutzki FM, Rossa S, Bauer H, Neumann C, Dockendorff K, Sandmann J, Frölich JC. Measurement of nitrite and nitrate in biological fluids by gas chromatography-mass spectrometry and by the Griess assay: Problems with the Griess assay - solutions by gas chromatography-mass spectrometry. Anal Biochem 1997;244:208-220.
27. [27] Bode-Böger SM, Böger RH, Kienke S, Junker W, Frölich JC. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996;219:598-603.
28. [28] Hafner D, Heinen E, Noack E. Mathematical analysis of concentration-response relationships. Drug Res 1977;27:1871-1873.
29. 2 generation and anti-aggregatory potency of prostacyclin. Prostaglandins 1977;14:1035-1042.
30. [30] Tsao PS, Theilmeier G, Singer AH, Leung LLK, Cooke JP. L-arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler Thromb 1994;14:1529-1533.
31. [31] Ishii H, Hirashi S, Kuboki M, Suguira T, Waku K, Kazama M. The effect of plasma on platelet function in hypercholesterolemic rabbits and the changes in fatty acid composition of the plasma. Thromb Res 1984;34:447-455.
32. 2-reactive species activate primed platelets in human whole blood. Am J Physiol 1993;264:H1582-H1587.
33. [33] Wu KK, Hoak JC. A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet 1974;2:924-926.
34. [34] Nelson AM. Diet therapy in coronary disease. Effect on mortality of high-protein, high-seafood, fat-controlled diet. Geriatrics 1972;27:103-116.
35. [35] Hohlfeld T, Scharnowski F, Braun M, Schrör K. Antiplatelet effects of ticlopidine are reduced in experimental hypercholesterolemia. Thromb Haemost 1994;71:112-118.
36. [36] Sinzinger H, Feigl W, Silberbaur K. Prostacyclin generation in atherosclerotic arteries. Lancet 1979;2:469.
37. 2 biosynthesis in atherosclerosis. Proc Natl Acad Sci USA 1988;85:4511-4515.
38. [38] FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984;310:1065-1068.
39. [39] Galle J, Busse R, Bassenge E. Hypercholesterolemia and atherosclerosis change vascular reactivity in rabbits by different mechanisms. Arterioscler Thromb 1991;11:1712-1718.
40. [40] Weissler B, Locher R, deGraaf J, Moser R, Sachinidis A, Vetter W. Low density lipoprotein subfractions increase thromboxane formation in endothelial cells. Biochem Biophys Res Commun 1993;192:1245-1250.
41. 2 and serotonin are possible mediators. Circ Res 1989;79:154-166.
42. [42] Meyers KM, Holmsen H, Searchord CL. Comparative study of platelet dense granule constituents. Am J Physiol 1982;243:R454-R461.
43. [43] Verbeuren TJ, Jordaens FH, Van Hove CE, Van Hoydonck AE, Herman AG. Release and vascular activity of endothelium-derived relaxing factor in atherosclerotic rabbit aorta. Eur J Pharmacol 1990;191:173-184.
44. [44] Shimokawa H, Vanhoutte P. Impaired endothelium-dependent relaxation to aggregating platelets and related vasoactive substances in porcine coronary arteries in hypercholesterolemia and atherosclerosis. Circ Res 1989;64:900-914.
45. [45] Heistad DD, Armstrong ML, Marcus ML, Piegors DJ, Mark AL. Augmented responses to vasoconstrictor stimuli in hypercholesterolemic and atherosclerotic monkeys. Circ Res 1984;54:711-718.
46. [46] Trezise DJ, Drew GM, Weston AH. Analysis of the depressant effect of the endothelium on contractions of rabbit isolated basilar artery to 5-hydroxy-tryptamine. Br J Pharmacol 1992;106:587-592.